Literature DB >> 16231119

SLE-associated transverse myelitis successfully treated with Rituximab (anti-CD20 monoclonal antibody).

D J Armstrong1, M T McCarron, G D Wright.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16231119     DOI： 10.1007/s00296-005-0068-1

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


× No keyword cloud information.
  8 in total

1.  Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus.

Authors:  Silverio Perrotta; Franco Locatelli; Angela La Manna; Lucia Cennamo; Piero De Stefano; Bruno Nobili
Journal:  Br J Haematol       Date:  2002-02       Impact factor: 6.998

2.  An open study of B lymphocyte depletion in systemic lupus erythematosus.

Authors:  Maria J Leandro; Jonathan C Edwards; Geraldine Cambridge; Michael R Ehrenstein; David A Isenberg
Journal:  Arthritis Rheum       Date:  2002-10

3.  Longitudinal myelitis associated with systemic lupus erythematosus: clinical features and magnetic resonance imaging of six cases.

Authors:  J F Téllez-Zenteno; J M Remes-Troche; R O Negrete-Pulido; L Dávila-Maldonado
Journal:  Lupus       Date:  2001       Impact factor: 2.911

Review 4.  Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature.

Authors:  B Kovacs; T L Lafferty; L H Brent; R J DeHoratius
Journal:  Ann Rheum Dis       Date:  2000-02       Impact factor: 19.103

5.  Systemic lupus erythematosus related transverse myelitis presenting longitudinal involvement of the spinal cord.

Authors:  Kato Yu-ko Kimura; Yoshihiko Seino; Yoshiyuki Hirayama; Takumi Aramaki; Hiroshi Yamaguchi; Hiroyuki Amano; Teruo Takano
Journal:  Intern Med       Date:  2002-02       Impact factor: 1.271

6.  Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy.

Authors:  R Weide; J Heymanns; A Pandorf; H Köppler
Journal:  Lupus       Date:  2003       Impact factor: 2.911

7.  B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.

Authors:  R John Looney; Jennifer H Anolik; Debbie Campbell; Raymond E Felgar; Faith Young; Lois J Arend; James A Sloand; Joseph Rosenblatt; Iñaki Sanz
Journal:  Arthritis Rheum       Date:  2004-08

8.  Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies.

Authors:  David P D'Cruz; Susana Mellor-Pita; Beatriz Joven; Giovanni Sanna; Judith Allanson; James Taylor; Munther A Khamashta; Graham R V Hughes
Journal:  J Rheumatol       Date:  2004-02       Impact factor: 4.666
  8 in total
  10 in total

Review 1.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

Review 2.  Lupoid sclerosis.

Authors:  Briele Keiserman; Luiz Fernando Garcias da Silva; Mauro W Keiserman; Carlos Alberto von Mühlen; Henrique Luiz Staub
Journal:  Rheumatol Int       Date:  2009-10-14       Impact factor: 2.631

Review 3.  Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity.

Authors:  Eleni I Kampylafka; Harry Alexopoulos; Marinos C Dalakas; Athanasios G Tzioufas
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

4.  Rituximab in the treatment of severe lupus myelopathy.

Authors:  Yan Ye; Jie Qian; Yueying Gu; Xiaoqing Chen; Shuang Ye
Journal:  Clin Rheumatol       Date:  2011-02-23       Impact factor: 2.980

5.  Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system.

Authors:  Mikiko Tokunaga; Kazuyoshi Saito; Daisuke Kawabata; Yoshitaka Imura; Takao Fujii; Shingo Nakayamada; Shizuyo Tsujimura; Masao Nawata; Shigeru Iwata; Taeko Azuma; Tsuneyo Mimori; Yoshiya Tanaka
Journal:  Ann Rheum Dis       Date:  2006-11-15       Impact factor: 19.103

6.  Dramatic Response of Lupus Enteritis, Nephritis, and Pancytopenia to Plasmapheresis and Rituximab.

Authors:  Adan Aftab; Nida Saleem; Syed Farhat Abbas; Zafar Ullah; Muhammad Haneef
Journal:  Case Rep Gastrointest Med       Date:  2022-06-06

Review 7.  [Rituximab in treatment for neuroimmunological diseases].

Authors:  A Schröder; G Ellrichmann; G Chehab; M Schneider; R A Linker; R Gold
Journal:  Nervenarzt       Date:  2009-02       Impact factor: 1.214

Review 8.  Myelopathy associated with mixed connective tissue disease: clinical manifestation, diagnosis, treatment, and prognosis.

Authors:  Yulei Hao; Meiying Xin; Shuang Wang; Di Ma; Jiachun Feng
Journal:  Neurol Sci       Date:  2019-05-21       Impact factor: 3.830

9.  Transverse myelitis as a presenting feature of late onset systemic lupus erythematosus.

Authors:  Hani Almoallim; Majidah Bukhari; Leena Alwafi; Gassan Wali
Journal:  Ann Saudi Med       Date:  2009 Mar-Apr       Impact factor: 1.526

Review 10.  Transverse myelitis.

Authors:  Shin C Beh; Benjamin M Greenberg; Teresa Frohman; Elliot M Frohman
Journal:  Neurol Clin       Date:  2013-02       Impact factor: 3.806
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.